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Few first-rate biologists start their
careers with only one ‘A-level’ (High
School qualification) and a job in a
copper wire factory. Fewer still go on
to command a research budget of
£250 million a year. But then Mike
Dexter, who takes over this summer
as director of the UK’s Wellcome
Trust, the world’s biggest medical
research charity, has always done
things his own way.
Dexter joins the Trust this month
from the Paterson Institute for
Cancer Research at the Christie
Hospital, Manchester, where 25
years’ work on the control of blood
cell development have gained him
international respect. He was the
first to discover, among other things,
how to grow stem cells in vitro. “It
was a seminal contribution and it
opened up generations of new
experiments,” says Gordon McVie,
director-general of the Cancer
Research Campaign, which funds the
institute. With more than 320 papers
under his belt and a fellowship of the
Royal Society, Dexter is regarded as
a scientist’s scientist.
But his success was not exactly
handed to him on a plate. The son of
a Manchester engineer and a
housewife, his first job was as a
trainee production manager at
Frederick Smith’s copper wire factory.
He realized he was bored after three
months, took a job as a technician at
the Paterson, got the extra ‘A-levels’
he needed at night school and went to
the University of Salford to read
biology in 1967, at the age of 22.
By then he had already married a
trainee radiographer, so he lived out
in a Cheshire village, not with his
fellow students in a hall of residence.
He was drawn to cancer research
partly by the shock of learning, on
returning from a holiday, that the
young son of the farm labourer who
lived next door had died of
leukaemia. It is because his feet have
always been on the ground that
Dexter is an intensely practical man
say his friends — and one who can
communicate with anybody.
Life continued to be tougher for
him than for many of his peers. He
did his PhD while helping to raise
twins, so research was juggled with
nappies and broken nights. The
relationship eventually ended; a
second marriage and two more
children followed. The experiences
made Dexter profoundly aware of the
need for a career structure in science
that allows parents, whether women
or men, to meet their responsibilities
without falling behind.
The Wellcome Trust’s decision to
appoint a respected scientist rather
than a business executive, as some
had feared, has reassured biomedical
researchers. Although Dexter is by
no means shy of industry — he co-
founded Therexsys, a gene therapy
start-up company — he is a
passionate defender of good science
and he sees the Trust’s job as
fostering excellence in research. “I
want to see people given the
freedom to develop ideas,” he says.
Pressure to publish, regardless of
quality, has put this freedom under
threat, he believes.
“There are occasions when you
are doing three to four years of bloody
good work, but not getting
publications out,” he says. “The more
difficult the problem the more I want
people to go into it, but the less likely
they are in the short term to come up
with the easy, quick solution.” Not
that he is offering anyone a meal
ticket. Since becoming the director of
the Paterson last year, he has gained a
reputation for rigour and, if necessary,
toughness.
Dexter’s areas of scientific
interest are outside the traditional
scope of the Wellcome Trust, whose
founder, Sir Henry Wellcome,
explicitly excluded cancer research
from its remit. In some eyes, this
makes Dexter a surprise choice for
the job. But Dexter does not think
of himself as a ‘cancer biologist’.
“It’s such a misleading term,” he
says. At the cellular
and molecular levels,
biomedical research
is not narrowly
restricted to specific
diseases, he argues.
In any case, Dexter is
considered to have an
excellent grasp of the
bigger biomedical
picture: he chaired
the Medical Research
Council’s Molecular
and Cellular Medicine Board
between 1994 and 1996.
He has no shortage of ideas about
where the Trust should put its
muscle next. For example, he is keen
to expand veterinary science,
particularly to tackle the problems
plaguing agriculture, such as BSE
(Bovine Spongiform Encephalopathy)
and salmonella. And he also wants
more research on unglamorous but
common diseases such as rheumatoid
arthritis.
Dexter is clearly someone who
has learned to live comfortably with
the absurd contradictions of life. He
knows how to let his hair down, say
friends: he has a reputation for
bringing a guitar to conferences, and
singing songs that get bawdier as the
evening progresses. (He admitted
this unprompted, although he
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The public (right) and private faces of
Mike Dexter. (Photographs courtesy
of Cheshire Life magazine.)
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Kew Millennium Seed
Bank Appeal
What is it famous for? For botanists
and horticulturalists, it is one of the
largest, most exciting conservation
projects ever undertaken. But anyone
outside the field is more likely to
have heard of the appeal’s patron —
TV naturalist Sir David Attenborough
— than of the seed bank itself.
How did it start? In 1974, The Royal
Botanic Gardens, Kew
(http://www.rbgkew.org.uk) started a
seed bank at Wakehurst Place in West
Sussex, UK, in an attempt to provide
a cache of some of the world’s
botanical genetic diversity. The seed
bank has successfully collected and
stored seeds of some 4,000 wild plant
species since 1974 and is now the
most comprehensive collection of
wild species in the world. (Most other
seed banks have been used only to
collect and store commercial seed.)
The Millennium Seed Bank Appeal
was launched on 31 May 1996. 
What is the aim? To extend the
existing seed bank to include almost
all the UK flora by the year 2000 and
a further 10% of the rest of the
world’s flora — a further 25,000
species — by 2010.
Why use seed banks? Seed banking
may prove the most effective and
economical means of ensuring the
survival of plant species. The
Millennium Seed Bank already holds
some of the most threatened of the
UK flora, like the clove-scented
broomrape (Orobanche caryophyllacae).
In 1992, the international Convention
on Biological Diversity formally
recognised the need for concerted
global action in this decade to slow
down the rate of loss of genes, species
and ecosystems. The convention
pragmatically acknowledged that
conservation of whole ecosystems
intact would probably be unattainable
and made recommendations for ex situ
conservation. In other words, “gather
ye rosebuds while ye may” because
you’ll probably need them later.
So, are seed banks simply a form of
stamp-collecting?  No. Plant species
earn their place in the seed bank on
the basis not only of rarity but also of
their potential. In the future,
reintroduction of species may prove
critical in halting land degradation and
in regeneration of ‘brownfield’ sites
— not to mention the pharmaceutical
wealth that could be held in many
plant species. It will be interesting to
see whether the chemicals giants will
be paying ‘bank charges’ for
withdrawals beyond the millennium.
Why base the bank at Kew? With more
than two centuries of plant collecting
and of horticultural expertise, it has
built up strong connections with
research institutes worldwide, which
will be essential for the collection of
seeds internationally.
Who provides the funding? The UK
Millennium Commission agreed to
grant up to £30 million on the basis
that matching funds could be raised.
By Autumn 1997 the appeal had
raised more than £17.4 million,
including £9.2 million from the
Wellcome Trust — perhaps because of
the biomedical potential of the cache.
wouldn’t sing any — but then we met
in the lobby of a rather posh hotel.)
He also reads poetry widely, from
Pablo Neruda to Wordsworth. And, to
the affectionate embarrassment of his
erstwhile bosses at the Cancer
Research Campaign, he has a
weakness for a quiet smoke.
Coming from outside the
hallowed league of ‘Oxbridge’,
London and Edinburgh, Dexter has
been seen as anti-Establishment.
“He’s certainly not a man in a grey
suit: I don’t think he will be anyone’s
poodle,” says Robin Weiss, head of
the Chester Beatty Laboratories at
the Institute of Cancer Research in
London. It would be wrong,
however, to portray him as a knee-
jerk rebel. “He’s not anti-The
System, he’s just not afraid to
criticise it,” says Gordon McVie.
“And he’s open to ideas wherever
they come from.”
He will be under pressure from
some researchers to make changes
within the Wellcome Trust. Critics
claim that the Trust is run as a
coterie, with major awards
sometimes appearing to land rather
close to some of its governors. If
Dexter has any sympathy with the
critics, he is not saying so. He says,
carefully, that the governors include
some of the best scientific brains in
Britain and that it would be alarming
if they were not being funded by
organisations such as the Trust and
the Medical Research Council.
Dexter’s friends do not expect
him to rush in and make feathers fly.
They think, instead, that he will do
what he has always done — listen to
all views carefully, including the
views of the hitherto unheard, and
then make up his own mind. Judging
by his track record so far, that looks
like good news for British
biomedicine.
Phyllida Brown is a science writer based in
London.
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The shrub Parkinsonia aculeata — stored in
the Millenium Seed Bank — is an example of
a ‘solid investment’ in seed banking terms. It
can be grown in moist tropical soil and in
desert washes, where it can help control
erosion of sandy soil. It can also be used to
treat fever, dysentery and as an antiseptic,
and for firewood, charcoal and construction.
